Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IM19 CAR-T Cell Therapy in Refractory Systemic Lupus Erythematosus
NCT06513429Recruiting
- Sponsor
- Peking University Third Hospital
- Start
- Jul 2024
- Primary completion
- Jan 2026
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Open-label, single-arm trial of IM19 in systemic lupus erythematosus (SLE), sponsored by Peking University Third Hospital. Primary endpoints: Change from baseline of SLEDAI-2K score at 90 days and Adverse events related to IM19 CAR-T cell therapy at 28 days. Started Jul 2024; status: recruiting.
02
Drugs
IM19
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT06513429.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06513429.